Table 1.
Demographic and cinical characteristics of patients with cilostazol and patients with ticlopidine
| Characteristic | Cilostazol (n = 15) | Ticlopidine (n = 13) | P value |
|---|---|---|---|
| Age (y): mean ± standard deviation (range) | 75.8 ± 7.9 (52–87) | 76.9 ± 5.5 (66–87) | 0.68 |
| Gender: male/female | 12/3 | 11/2 | 0.75 |
| Hypertension: +/− | 12/3 | 11/2 | 0.75 |
| Hyperlipidemia: +/− | 6/9 | 5/8 | 0.93 |
| Diabetes mellitus: +/− | 10/5 | 6/7 | 0.27 |
| Smoking: +/− | 13/2 | 12/1 | 0.63 |
| Renal insufficiency (serum creatinine >2mg/dL) | 3 | 3 | 0.84 |
| Respiratory tract disease | 4 | 2 | 0.40 |
| History of ischemic heart disease: +/− | 8/7 | 8/5 | 0.66 |
| History of stroke: +/− | 6/9 | 5/8 | 0.93 |
| Fontaine stage of peripheral artery disease | |||
| IIb | 9 | 9 | |
| III | 3 | 0 | |
| IV | 3 | 4 | |
| Complete vessel occlusion: +/− | 13/2 | 12/1 | 0.63 |
| Indication for stent placement | |||
| Residual stenosis | 9 | 7 | |
| Flow-limiting dissection | 6 | 6 | |
| Cumulative length of stents (cm): mean ± standard deviation (range) | 14.1 ± 5.5 (3–21) | 18.8 ± 8.3 (7–34) | 0.10 |
| Inflow disease: +/− | 4/11 | 2/11 | 0.47 |
| Poor runoff: +/− | 3/12 | 6/7 | 0.14 |